Celgene (BUE:CELG) OCF Margin %: 48.05% (As of Sep. 2019)


What is Celgene OCF Margin %?

Celgene BUE:CELG 10 OCF Margin % is 48.05% as of Sep. 2019. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Celgene's Cash Flow from Operations for the three months ended in Sep. 2019 was ARS121,471.27 Mil. Celgene's Revenue for the three months ended in Sep. 2019 was ARS252,785.52 Mil. Therefore, Celgene's OCF Margin % for the quarter that ended in Sep. 2019 was 48.05%.

As of today, Celgene's current OCF Yield % is 0.00%.

The historical rank and industry rank for Celgene's OCF Margin % or its related term are showing as below:


BUE:CELG's OCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.95
* Ranked among companies with meaningful OCF Margin % only.

Celgene OCF Margin % Related Terms

Celgene OCF Margin % Historical Data

* Premium members only.

The historical data trend for Celgene's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celgene OCF Margin % Chart

Celgene Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.59 30.09 37.09 40.34 33.84

Celgene Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.43 58.04 36.67 49.25 48.05

Celgene OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Celgene's OCF Margin for the fiscal year that ended in Dec. 2018 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2018 )/Revenue (A: Dec. 2018 )
=194972.565/576170.135
=33.84 %

Celgene's OCF Margin for the quarter that ended in Sep. 2019 is calculated as

OCF Margin=Cash Flow from Operations (Q: Sep. 2019 )/Revenue (Q: Sep. 2019 )
=121471.27/252785.516
=48.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 48.05% mean?
Celgene (BUE:CELG) has a OCF Margin % of 48.05% as of Sep. 2019. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Celgene and its competitors.
Is Celgene's OCF Margin % too high?
Celgene's current OCF Margin % is 48.05%. The Drug Manufacturers industry median OCF Margin % is 9.95. Celgene's value of 48.05% is 382.9% above this industry median. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's OCF Margin % compare to GILD and BIIB?
Celgene's OCF Margin % of 48.05% can be compared against companies in the Drug Manufacturers industry. The industry median OCF Margin % is 9.95. Celgene's value of 48.05% is 382.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celgene's current OCF Margin % of 48.05% is 382.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Celgene and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celgene's current OCF Margin % is 48.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current OCF Margin % of 48.05%. The current OCF Margin % is 48.05% and 382.9% above the Drug Manufacturers industry median of 9.95. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Celgene (BUE:CELG), the current OCF Margin % is 48.05% as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celgene Business Description

Address 86 Morris Avenue, Summit, NJ, USA, 07901
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.